Principal Financial Group Inc. Has $8.73 Million Stock Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Principal Financial Group Inc. lessened its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 0.2% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 218,172 shares of the company’s stock after selling 402 shares during the period. Principal Financial Group Inc.’s holdings in Amphastar Pharmaceuticals were worth $8,727,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Quadrant Capital Group LLC raised its stake in shares of Amphastar Pharmaceuticals by 27.8% during the 4th quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after purchasing an additional 223 shares in the last quarter. Bridge City Capital LLC raised its position in Amphastar Pharmaceuticals by 0.8% during the first quarter. Bridge City Capital LLC now owns 34,773 shares of the company’s stock worth $1,527,000 after acquiring an additional 275 shares in the last quarter. Blue Trust Inc. lifted its stake in Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares during the last quarter. Texas Permanent School Fund Corp grew its position in shares of Amphastar Pharmaceuticals by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 32,704 shares of the company’s stock valued at $1,436,000 after acquiring an additional 424 shares during the period. Finally, Principal Securities Inc. acquired a new position in shares of Amphastar Pharmaceuticals during the 4th quarter worth about $34,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently commented on AMPH. Piper Sandler reduced their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. StockNews.com upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, September 2nd. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $63.00.

Insider Transactions at Amphastar Pharmaceuticals

In related news, Director Floyd F. Petersen sold 3,000 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the transaction, the director now directly owns 75,409 shares in the company, valued at $3,504,256.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Floyd F. Petersen sold 3,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares in the company, valued at $3,504,256.23. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Richard K. Prins sold 17,101 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $43.07, for a total value of $736,540.07. Following the completion of the sale, the director now owns 33,971 shares of the company’s stock, valued at $1,463,130.97. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,979 shares of company stock valued at $1,795,507. 27.10% of the stock is currently owned by corporate insiders.

Amphastar Pharmaceuticals Trading Down 0.1 %

Shares of AMPH stock opened at $45.38 on Friday. Amphastar Pharmaceuticals, Inc. has a 12-month low of $36.56 and a 12-month high of $65.92. The firm has a 50 day moving average price of $42.68 and a two-hundred day moving average price of $42.87. The company has a quick ratio of 2.63, a current ratio of 3.52 and a debt-to-equity ratio of 0.82. The company has a market capitalization of $2.22 billion, a PE ratio of 15.70, a price-to-earnings-growth ratio of 0.92 and a beta of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings results on Wednesday, August 7th. The company reported $0.85 earnings per share for the quarter, topping the consensus estimate of $0.75 by $0.10. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. The business had revenue of $182.39 million during the quarter, compared to analysts’ expectations of $171.29 million. As a group, analysts predict that Amphastar Pharmaceuticals, Inc. will post 3.71 earnings per share for the current year.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.